Ipilimumab-induced necrotic myelopathy in a patient with metastatic melanoma: A case report and review of literature

Journal of Oncology Pharmacy Practice

Volumn 22, Issue 3, 2016, Pages 537-542

  Abdallah, Al Ola ^a   Herlopian, Aline ^a   Ravilla, Rahul ^a   Bansal, Meghana ^a   Chandra Reddy, Sowmya ^a   Mahmoud, Fade ^a   Ong, Shirley ^a   Gokden, Murat ^b   Hutchins, Laura ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

immune related adverse events; Ipilimumab; progressive necrotic myelopathy

Indexed keywords

DEXAMETHASONE; INFLIXIMAB; IPILIMUMAB; PREDNISONE; IMMUNOLOGICAL ANTINEOPLASTIC AGENT;

ADULT; ASEPTIC MENINGITIS; CANCER PATIENT; CASE REPORT; DISEASE SEVERITY; DRUG WITHDRAWAL; FEMALE; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MENINGO RADICULO NEURITIS; METASTATIC MELANOMA; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MYOSITIS; NECROTIC MYELOPATHY; NEURITIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIORITY JOURNAL; REVIEW; SPINAL CORD DISEASE; TEMPORAL ARTERITIS; BONE NECROSIS; CHEMICALLY INDUCED; DIAGNOSTIC IMAGING; MELANOMA; SKIN TUMOR;

ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; FEMALE; HUMANS; IPILIMUMAB; MELANOMA; MIDDLE AGED; OSTEONECROSIS; SKIN NEOPLASMS; SPINAL CORD DISEASES;

EID: 84964294839     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155215572932     Document Type: Review

References (34)

1. Pardoll DM,. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264.
2. Peggs KS, Quezada SA, Korman AJ, et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006; 18: 206-213.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
4. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2009; 11: 155-164.
5. Weber J,. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58: 823-830.
6. Ibrahim R, Berman D, de Pril V, et al. Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol 2011; 29. abstract no. 8583.
7. Hunter G, Voll C, Robinson CA,. Autoimmune inflammatory myopathy after treatment with ipilimumab. Canadian J Neurol Sci 2009; 36: 518-520.
8. Yang JC, Hughes M, Kammula U, et al. Ipilimumab (anti- CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30: 825-830.
9. Bompaire F, Mateus C, Taillia H, et al. Severe meningoradiculo-nevritis associated with ipilimumab. Investig New Drugs 2012; 30: 2407-2410.
10. Korn EL, Liu PY, Lee SJ, et al. Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008; 26: 527-534.
11. Wilgenhof S, Neyns B,. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient. Ann Oncol 2011; 22: 991-993.
12. Maur M, Tomasello C, Frassoldati A, et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012; 30: e76-8.
13. Lester E, Feld E, Kinzie J, et al. Necrotizing myelopathy complicating Hodgkin's disease. Arch Neurol 1979; 36: 583-585.
14. Kim RC,. Necrotizing myelopathy. AJNR 1991; 12: 1084-1086.
15. Wiley CA, VanPatten PD, Carpenter PM, et al. Acute ascending necrotizin myelopathy caused by herpes simplex virus type 2. Neurology 1987; 37: 1791-1794.
16. Nakagawa M, Kubota R, Takenaga S, et al. Nationwide survey of necrotizing myelopathy associated with malignancy in Japan. Rinsho Shinkeigaku 1991; 31: 512-515.
17. Katz JD, Ropper AH,. Progressive necrotic myelopathy: clinical course in 9 patients. Arch Neurol 2000; 57: 355-361.
18. Ojeda VJ,. Necrotizing myelopathy associated with malignancy. A clinicopathological study of two cases and literature review. Cancer 1984; 53: 111-123.
19. Misumi H, Ishibashi H, Kanayama K, et al. Necrotizing myelopathy associated with hepatocellular carcinoma. JPN J Med 1988; 27: 333-336.
20. Yervoy (ipilimumab) Injection, prescribing information. Princeton, NJ: Bristol- Myers Squibb; March 2011, http://packageinserts.bms.com (accessed 18 January 2012).
21. Patel SP, Woodman SE,. Profile of ipilimumab and its role in treatment of metastatic melanoma. Drug Des Devel Ther 2011; 5: 489-495.
22. Andrews S, Holden R,. Characteristics and management of immune-related adverse effects associated with ipilimumab, a new immunotherapy for metastatic melanoma. Cancer Manag Res 2012; 4: 299-307.
23. Leach BC, Kulbersh JS, Day TA, et al. Cranial neuropathy as a presenting sign of recurrent aggressive skin cancer. Dermatol Surg 2008; 34: 483-497.
24. Painter TJ, Chaljub G, Sethi R, et al. Intracranial and intraspinal meningeal melanocytosis. AJNR Am J Neuroradiol 2000; 21: 1349-1353.
25. Manousakis G, Koch J, Sommerville B, et al. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve 2013; 48: 440-444.
26. Tarhini A, Lo E, Minor DR,. Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm 2010; 25: 601-613.
27. Von Euw E, Chodon T, Attar N, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 2009; 7: 35-35.
28. Bettelli E, Oukka M, Kuchroo VK,. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8(4): 345-350.
29. Callahan MK, Yang A, Tandon S, et al. Evaluation of serum IL-17 levels during ipilimumab therapy: correlation with colitis. In: ASCO meeting abstracts 2505, 2011.
30. Clemente CG, Mihm MC Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-1310.
31. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic Tlymphocyte antigen-4. J Clin Oncol 2005; 23: 6043-6053.
32. Lemech C, Arkenau HT,. Novel treatments formetastatic cutaneous melanoma and the management of emergent toxicities. Clin Med Insights, Oncol 2012; 6: 53-66.
33. Weber JS, Kähler KC, Hauschild A,. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012; 30: 2691-2697.
34. Johnston RL, Lutzky J, Chodhry A, et al. Cytotoxic T-lymphocyte-associated antigen 4 antibody-induced colitis and its management with infliximab. Dig Dis Sci 2009; 54: 2538-2540.